The FDA recently approved Opsynvi, developed by Johnson & Johnson, for treating pulmonary arterial hypertension (PAH) in adults, marking a significant advancement in PAH management.
Translate (automatic translation - please excuse any mistakes) »
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.